Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review

医学 间质性肺病 重症监护医学 疾病 肺 内科学 病理
作者
Koushan Kouranloo,Mrinalini Dey,Helen Elwell,Veronica Yioe,Lisa G. Spencer,Caroline V. Cotton
出处
期刊:Rheumatology [Oxford University Press]
卷期号:64 (1): 45-55 被引量:18
标识
DOI:10.1093/rheumatology/keae403
摘要

OBJECTIVES: Anti-synthetase syndrome (ASS) is a chronic autoimmune condition, with interstitial lung disease (ILD) being a key feature. This systematic literature review (SLR; CRD42023416414) aimed to summarize treatments and outcomes of ILD associated with ASS (ASS-ILD). METHODS: Databases were searched for articles discussing ASS-ILD management and outcomes, published 1946-September 2023. Screening and data extraction were performed by two reviewers. Meta-analysis, using a random effects model, and paired t-tests were undertaken where appropriate to evaluate post-treatment-change in pulmonary function tests. RESULTS: Ten articles were included, comprising 514 patients: 67.8% female, mean age 52.4 years (s.d. 4.6). Baseline high-resolution CT was documented in 447 patients (86.9%); the most common pattern was non-specific interstitial pneumonia (n = 220; 49.2%). The most common myositis-associated autoantibody was anti-Jo1 (48%), with 27.8% having associated anti-Ro52 antibodies. Pooled estimate, after meta-analysis, for baseline forced vital capacity (FVC) was 60.8% predicted (s.e. 2.1) and for diffusion capacity of lungs for carbon monoxide (DLco) was 49.8% (s.e. 3.5). After 1 year, pooled improvement in FVC was 14.1% from baseline (s.e. 3.1) and in DLco was 15.1% (s.e. 2.8). Paired t-test demonstrated significant overall improvement in FVC (P = 0.007) and DLco (P = 0.002). Patients receiving rituximab had 12.2% improvement in FVC and 2.9% increase in DLco at 1 year; for patients receiving CYC, there was 17% improvement and 6.3% increase, respectively. Twenty-eight deaths were reported. CONCLUSION: Our SLR, the first to summarize management and outcomes of ASS-ILD, found no conclusive difference between effectiveness of treatments. More robust trials are required to reduce morbidity and mortality resulting from ASS-ILD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文败类的应助被淡淡青枫采纳,获得10
1秒前
2秒前
山海不远发布了新的文献求助10
3秒前
uniphoton完成签到,获得积分10
4秒前
fatal发布了新的文献求助10
6秒前
111发布了新的文献求助10
6秒前
粥粥粥完成签到 ,获得积分10
7秒前
ding的应助被木木采纳,获得10
8秒前
叶上初阳完成签到,获得积分0
8秒前
干咸鱼叔叔完成签到,获得积分10
9秒前
GoGoGo完成签到,获得积分10
10秒前
hitech的应助被fatal采纳,获得10
12秒前
科研通AI6.2的应助被山海不远采纳,获得30
13秒前
含蓄书桃完成签到 ,获得积分10
13秒前
spark发布了新的文献求助10
14秒前
Crazy鑫完成签到,获得积分10
16秒前
17秒前
18秒前
快乐鼠完成签到,获得积分10
20秒前
21秒前
21秒前
WLLLR发布了新的文献求助10
21秒前
桓某人发布了新的文献求助10
22秒前
24秒前
choin6688_完成签到 ,获得积分10
25秒前
lyj发布了新的文献求助10
25秒前
眼睛大泥猴桃完成签到,获得积分10
25秒前
隐形曼青的应助被乐乐采纳,获得10
26秒前
解洙完成签到 ,获得积分10
26秒前
27秒前
王小聪明发布了新的文献求助10
28秒前
wg发布了新的文献求助10
28秒前
chongtse发布了新的文献求助10
28秒前
molihuakai的应助被烟酒僧采纳,获得10
30秒前
李健的应助被laola采纳,获得10
30秒前
rainy完成签到,获得积分10
32秒前
无限孤云完成签到,获得积分10
34秒前
淡淡青枫发布了新的文献求助10
34秒前
默默完成签到 ,获得积分10
35秒前
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196